DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL
2
Small molecule
Investigational
Unknown
Unknown
Sarcoma, Ewing
Unknown
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL
×
Maximum Phase:
2
First Approval:
None
UNII:
6PHSP9EORV
Molecule Type:
Small molecule
Molecular Formula:
C65H116N6O21
Molecular Weight:
1317.66
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MT-3995
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Non-alcoholic Fatty Liver Disease
Mineralocorticoid receptor antagonist
MT-3995
×
Maximum Phase:
2
First Approval:
None
UNII:
832663U2NB
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BL22
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Leukemia; Leukemia, Hairy Cell
CD22 binding agent
BL22
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor binding agent
TELISOTUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
976X9VXC3Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2
2
Unknown
Investigational
Unknown
Unknown
Colonic Neoplasms; Coronary Disease; Severe Acute Respiratory Syndrome
Unknown
RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2
×
Maximum Phase:
2
First Approval:
None
UNII:
3TTT9ZD93F
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CARFENTANIL
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
Unknown
CARFENTANIL
×
Maximum Phase:
2
First Approval:
None
UNII:
LA9DTA2L8F
Molecule Type:
Small molecule
Molecular Formula:
C24H30N2O3
Molecular Weight:
394.51
AlogP:
3.68
PSA:
49.85
HBD:
0.0
HBA:
#RotB:
7.0
Source:
PAMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Unknown
MAP kinase p38 alpha inhibitor
PAMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
8S2C9V11K4
Molecule Type:
Small molecule
Molecular Formula:
C19H20F2N4O4
Molecular Weight:
406.39
AlogP:
1.94
PSA:
109.5
HBD:
3.0
HBA:
#RotB:
8.0
Source:
BRECANAVIR
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
HIV-1 protease inhibitor
BRECANAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
E367I8C7FI
Molecule Type:
Small molecule
Molecular Formula:
C33H41N3O10S2
Molecular Weight:
703.84
AlogP:
3.87
PSA:
154.98
HBD:
2.0
HBA:
#RotB:
14.0
Source:
BMS-833923
2
Small molecule
Investigational
Unknown
Unknown
Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Leukemia
Smoothened homolog antagonist
BMS-833923
×
Maximum Phase:
2
First Approval:
None
UNII:
41J7ZJ239R
Molecule Type:
Small molecule
Molecular Formula:
C30H27N5O
Molecular Weight:
473.58
AlogP:
6.32
PSA:
78.94
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DAPIROLIZUMAB PEGOL
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
CD40 ligand inhibitor
DAPIROLIZUMAB PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
N4606MB5HM
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUNOBINOP
2
Small molecule
Investigational
Unknown
Unknown
Pain; Sleep Initiation and Maintenance Disorders
Unknown
SUNOBINOP
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H33N3O3
Molecular Weight:
435.57
AlogP:
4.62
PSA:
75.43
HBD:
1.0
HBA:
#RotB:
3.0
Source:
PHENYLACETATE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PHENYLACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EBDAROKIMAB
2
Antibody
Investigational
Unknown
Unknown
Psoriasis
Interleukin-12 inhibitor
EBDAROKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZEDENOLEUCEL
2
Cell
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
ZEDENOLEUCEL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LAZUVAPAGON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LAZUVAPAGON
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H32N4O3
Molecular Weight:
460.58
AlogP:
3.59
PSA:
87.46
HBD:
2.0
HBA:
#RotB:
5.0
Source:
SIMUROSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Cell division cycle 7-related protein kinase inhibitor
SIMUROSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
LST350G3XU
Molecule Type:
Small molecule
Molecular Formula:
C17H19N5OS
Molecular Weight:
341.44
AlogP:
2.84
PSA:
77.67
HBD:
2.0
HBA:
#RotB:
2.0
Source:
MESDOPETAM
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
MESDOPETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
HD4QV8GX26
Molecule Type:
Small molecule
Molecular Formula:
C12H18FNO3S
Molecular Weight:
275.35
AlogP:
1.61
PSA:
55.4
HBD:
1.0
HBA:
#RotB:
7.0
Source:
7-HYDROXYSTAUROSPORINE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
7-HYDROXYSTAUROSPORINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-4136309
2
Unknown
Investigational
Unknown
Unknown
Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Hepatitis C, Chronic; Osteoarthritis, Knee
C-C chemokine receptor type 2 antagonist
PF-4136309
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RAZUPROTAFIB
2
Small molecule
Investigational
Unknown
Unknown
Retinal Vein Occlusion
Receptor-type tyrosine-protein phosphatase beta inhibitor
RAZUPROTAFIB
×
Maximum Phase:
2
First Approval:
None
UNII:
0WAX4UT396
Molecule Type:
Small molecule
Molecular Formula:
C26H26N4O6S3
Molecular Weight:
586.72
AlogP:
4.45
PSA:
146.72
HBD:
4.0
HBA:
#RotB:
11.0
Source:
OLOROFIM
2
Small molecule
Investigational
Unknown
Unknown
Aspergillosis; Leukemia, Myeloid, Acute; Liver Diseases; Mycoses
Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
OLOROFIM
×
Maximum Phase:
2
First Approval:
None
UNII:
T34SH2H9HI
Molecule Type:
Small molecule
Molecular Formula:
C28H27FN6O2
Molecular Weight:
498.56
AlogP:
4.08
PSA:
83.36
HBD:
1.0
HBA:
#RotB:
6.0
Source:
CARMOTEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
CARMOTEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
9810NUL4D1
Molecule Type:
Small molecule
Molecular Formula:
C21H24N2O4
Molecular Weight:
368.43
AlogP:
2.5
PSA:
94.58
HBD:
4.0
HBA:
#RotB:
7.0
Source:
IVUXOLIMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma, Follicular; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Neoplasms
Tumor necrosis factor receptor superfamily member 4 agonist
IVUXOLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
APS3IS9D6W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AXL1717
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AXL1717
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Dementia
Unknown
TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4J4Z8788N8
Molecule Type:
Small molecule
Molecular Formula:
C4H6O6
Molecular Weight:
150.09
AlogP:
-2.12
PSA:
115.06
HBD:
4.0
HBA:
#RotB:
3.0
Source:
AMISELIMOD
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AMISELIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
358M5150LY
Molecule Type:
Small molecule
Molecular Formula:
C19H30F3NO3
Molecular Weight:
377.45
AlogP:
3.67
PSA:
75.71
HBD:
3.0
HBA:
#RotB:
12.0
Source:
FERUCARBOTRAN
2
Unknown
Investigational
Unknown
Unknown
Unknown
Diagnostic
FERUCARBOTRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RUZASVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Nonstructural protein 5A inhibitor
RUZASVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
LX752BD95Y
Molecule Type:
Small molecule
Molecular Formula:
C49H56N10O7S
Molecular Weight:
929.12
AlogP:
8.45
PSA:
201.69
HBD:
4.0
HBA:
#RotB:
12.0
Source:
ROVELIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin alpha-L/beta-2 (LFA-1) antagonist
ROVELIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XLB16RJ01B
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CHIAURANIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Lymphoma, Non-Hodgkin; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma
Serine/threonine-protein kinase Aurora-B inhibitor
CHIAURANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
F40IRN5981
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INS316
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
INS316
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BALOXAVIR
2
Small molecule
Investigational
Unknown
Unknown
Influenza, Human
Polymerase acidic protein inhibitor
BALOXAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
4G86Y4JT3F
Molecule Type:
Small molecule
Molecular Formula:
C24H19F2N3O4S
Molecular Weight:
483.5
AlogP:
2.98
PSA:
75.01
HBD:
1.0
HBA:
#RotB:
1.0
Source:
GSK2110183
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK2110183
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOCLADESINE
2
Small molecule
Investigational
Unknown
Unknown
Colorectal Neoplasms; Multiple Myeloma
Unknown
TOCLADESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
BQ94Z7E5OR
Molecule Type:
Small molecule
Molecular Formula:
C10H11ClN5O6P
Molecular Weight:
363.65
AlogP:
-0.16
PSA:
154.84
HBD:
3.0
HBA:
#RotB:
1.0
Source:
SSR-150106
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
SSR-150106
×
Maximum Phase:
2
First Approval:
None
UNII:
5WX0OAF07I
Molecule Type:
Small molecule
Molecular Formula:
C23H21F3N2
Molecular Weight:
382.43
AlogP:
5.59
PSA:
16.13
HBD:
0.0
HBA:
#RotB:
4.0
Source:
1
2
…
198
199
200
201
202
203
204
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA